Евразийские клинические рекомендации по диагностике и лечению фибрилляции предсердий у взрослых (2025)

В настоящем документе представлены актуальные на сегодняшний день рекомендации по диагностике и лечению фибрилляции (ФП) и трепетания предсердий у взрослых. Рекомендации разрабатывались для помощи врачу в выборе оптимальной стратегии лечения с учетом его влияния на исходы, соотношения пользы и риска при использовании того или иного метода диагностики и лечения. При разработке данных рекомендаций все участники рабочей группы руководствовались принципами доказательной медицины. Основанием для пересмотра прошлой версии Евразийских клинических рекомендаций (2019 г.) стало достаточно большое количество рандомизированных клинических исследований, завершённых в период 2019-2024 гг., оказавших влияние на многие аспекты как консервативного, так и интервенционного ведения пациентов, которые были учтены в Клинических рекомендациях Европейского общества кардиологов (2024г.), Американской ассоциации сердца/Американской коллегии кардиологов (2023 г.). При составлении обновлённой версии рекомендаций учитывались не только новые достижения медицинской науки, но и предпринимались попытки адаптации к региональным особенностям систем здравоохранения и оказания медицинской помощи, лекарственному обеспечению и популяционно-демографическим особенностям Евразийского региона.

1. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В., Давтян К.В., Драпкина О.М., Кропачева Е.С., Кучинская Е.А., Лайович Л.Ю., Миронов Н.Ю., Мишина И.Е., Панченко Е.П., Ревишвили А.Ш., Рзаев Ф.Г., Татарский Б.А., Уцумуева М.Д., Шахматова О.О., Шлевков Н.Б., Шпектор А.В., Андреев Д.А., Артюхина Е.А., Барбараш О.Л., Галявич А.С., Дупляков Д.В., Зенин С.А., Лебедев Д.С., Михайлов Е.Н., Новикова Н.А., Попов С.В., Филатов А.Г., Шляхто Е.В., Шубик Ю.В. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. https://doi.org/10.15829/1560-4071-2021-4594

2. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. PMID: 39210723. https://doi.org/10.1093/eurheartj/ehae176

3. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. https://doi.org/10.1161/CIR.0000000000001193. Epub 2023 Nov 30. Erratum in: Circulation. 2024 Jan 2;149(1):e167. https://doi.org/10.1161/ CIR.0000000000001207. Erratum in: Circulation. 2024 Feb 27;149(9):e936. https://doi.org/10.1161/CIR.0000000000001218. Erratum in: Circulation. 2024 Jun 11;149(24):e1413. PMID: 38033089; PMCID: PMC11095842. https://doi.org/10.1161/CIR.0000000000001263

4. Голицын С.П., Панченко Е.П., Кропачева Е.С., Лайович Л.Ю., Майков Е.Б., Миронов Н.Ю., Шахматова О.О. Диагностика и лечение фибрилляции предсердий. Евразийский Кардиологический Журнал. 2019;(4):4-85. https://doi.org/10.38109/2225-1685-2019-4-4-85

5. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423-434. https://doi.org/10.1093/europace/eun369

6. Shkolnikova M.A., Ildarova R.A., Shcherbakova N.V., Polyakova E.B., Jdanov D.A., Shkolnikov V.M., Mikhaylov E.N., Shalnova S.A. Atrial fibrillation among russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a population-based study. Journal of Geriatric Cardiology. 2020;17(2):74-84. https://doi.org/10.11909/j.issn.1671-5411.2020.02.002

7. Миронова Е.С., Миронов Н.Ю., Миронова Н.А., Новиков П.С., Новиков И.А., Лайович Л.Ю., Майков Е.Б., Голицын С.П. Электрофизиологические параметры сердца и результаты противоаритмического лечения у больных с пароксизмальной формой фибрилляции предсердий, идиопатической и в сочетании с гипертонической болезнью. Кардиология. 2019;59(8):39-46. https://doi.org/10.18087/cardio.2019.8.n644

8. Миронова Е.С., Миронова Н.А., Шарф Т.В., Ефремов Е.Е., Азьмуко А.А., Молокоедов А.С., Зыков К.А., Голицын С.П. Аутоантитела к M2-холинорецепторам как потенциальный фактор развития аритмии у больных пароксизмальной формой фибрилляции предсердий. Терапевтический архив. 2019;91(9):101-107. https://doi.org/10.26442/00403660.2019.09. 000280

9. Щербакова Н.В., Мешков А.Н., Бойцов С.А. Применение метода секвенирования экзомов для диагностики предрасположенности к комплексным заболеваниям в профилактической медицине. Кардиоваск. Тер. и проф. 2013;12(6):24-28.

10. Мясников Р.П., Щербакова Н.В., Куликова О.В., Мешков А.Н., Харлап М.С., Киселева А.В., Жарикова А.А., Дадали Е.Л., Семенова Н.А., Корецкий С.Н., Благова О.В., Мершина Е.А., Синицын В.Е., Драпкина О.М., Бойцов С.А. Мутация гена DES в семье пробанда с миофибриллярной миопатией и развитием некомпактной кардиомиопатии, приведшей к трансплантации сердца. Российский кардиологический журнал 2017;10(150):9–16. https://doi.org/http://dx.doi.org/10.15829/1560-4071-2017-10-9-16

11. Щербакова Н.В., Воинова В.Ю., Школьникова М.А. Генетика и сердце: основания для внедрения генетического тестирования в клиническую практику. Педиатрия им. Г.Н. Сперанского. 2020;99(3):8–15. https://doi.org/10.24110/0031-403X-2020-99-3-8-15

12. Акрамова Э.Г. Характеристика нарушений ритма сердца у больных хронической обструктивной болезнью легких. Клиническая медицина. 2013;91(2):41-44.

13. Хамитова Р.Я., Лоскутов Д.В., Акрамова Э.Г. Сравнительный анализ взаимосвязей кардиологической заболеваемости взрослого населения и социально-экономических показателей в регионах России. Социальные аспекты здоровья населения [сетевое издание] 2022;68(3):5. https://doi.org/10.21045/2071-5021-2022-68-3-5

14. Апарина О.П., Чихирева Л.Н., Миронова Н.А., Миронова Е.С., Бакалов С.А. Роль структурно-функциональных изменений предсердий в развитии и прогрессировании фибрилляции предсердий. Терапевтический архив. 2014;86(1):71-77.

15. Акрамова Э.Г. Клиническая значимость продольной деформации левого желудочка при ишемической болезни сердца и некоронарогенной патологии. Казанский мед. ж. 2019;100(2):295- 302. https://doi.org/10.17816/KMJ2019-295

16. Родионова Е.С., Миронова Н.А., Апарина О.П., Рогова М.М., Зыков К.А., Голицын С.П. Роль аутоиммунных реакций в развитии нарушений ритма и проводимости сердца. Терапевтическийархив. 2012;4:74-78.

17. Костюкевич М.В., Зыков К.А., Миронова Н.А., Агапова О.Ю., Шевелев А.Я., Ефремов Е.Е., Власик Т.Н., Голицын С.П. Роль аутоантител к ß1-адренорецептору при сердечно-сосудистых заболеваниях. Кардиология. 2016; 56 (12): 82-91. https://doi.org/10.18565/cardio.2016.12.82-91

18. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation — a translational appraisal. Physiol Rev 2010

19. Haissaguerre M. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. Heart Rhythm. 2024 Jun;21(6):713-714. PMID: 38816145. https://doi.org/10.1016/j.hrthm.2024.03.046

20. Wynn G.J., Todd D.M., Webber M., Bonnett L., McShane J., Kirchhof P., Gupta D. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16:965-972. https://doi.org/10.1093/europace/eut395

21. Schnabel R.B., Pecen L., Ojeda F.M., Lucerna M., Rzayeva N., Blankenberg S., et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103:1024–30. https://doi.org/10.1136/heartjnl-2016-310406

22. Kirchhof P., Ammentorp B., Darius H., De Caterina R., Le Heuzey J.Y., Schilling R.J., Schmitt J., Zamorano J.L. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events — European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14. https://doi.org/10.1093/europace/eut263

23. Yamashita T., Suzuki S., Inoue H., Akao M., Atarashi H., Ikeda T., Okumura K., Koretsune Y., Shimizu W., Tsutsui H., Toyoda K., Hirayama A., Yasaka M., Yamaguchi T., Teramukai S., Kimura T., Kaburagi J., Takita A. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):202-213. PMID: 33822030; PMCID: PMC8888123. https://doi.org/10.1093/ehjqcco/qcab025

24. Svennberg E., Stridh M., Engdahl J., Al-Khalili F., Friberg L., Frykman V., et al. Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation. Europace 2017;19:1449-53. https://doi.org/10.1093/europace/euw286

25. Halcox J.P.J., Wareham K., Cardew A., Gilmore M., Barry J.P., Phillips C., et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation 2017;136:1784–94. https://doi.org/10.1161/CIRCULATIONAHA.117.030583

26. Duarte R, Stainthorpe A, Greenhalgh J, Richardson M, Nevitt S, Mahon J, et al. Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. Health Technol Assess 2020;24:1- 164. https://doi.org/10.3310/hta24030

27. Lowres N., Neubeck L., Redfern J., Freedman S.B. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-222. https://doi.org/10.1160/th13-02-0165

28. Engdahl J., Andersson L., Mirskaya M., Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930-937. https://doi.org/10.1161/circulationaha.112.126656

29. Gladstone D.J., Spring M., Dorian P., Panzov V., Thorpe K.E., Hall J., Vaid H., O’Donnell M., Laupacis A., Cote R., Sharma M., Blakely J.A., Shuaib A., Hachinski V., Coutts S.B., Sahlas D.J., Teal P., Yip S., Spence J.D., Buck B., Verreault S., Casaubon L.K., Penn A., Selchen D., Jin A., Howse D., Mehdiratta M., Boyle K., Aviv R., Kapral M.K., Mamdani M.; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-2477. https://doi.org/10.1056/nejmoa1311376

30. Sanna T., Diener H.C., Passman R.S., Di Lazzaro V., Bernstein R.A., Morillo C.A., Rymer M.M., Thijs V., Rogers T., Beckers F., Lindborg K., Brachmann J.; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-2486. https://doi.org/10.1056/nejmoa1313600

31. Wachter R., Groschel K., Gelbrich G., Hamann G.F., Kermer P., Liman J., Seegers J., Wasser K., Schulte A., Jurries F., Messerschmid A., Behnke N., Groschel S., Uphaus T., Grings A., Ibis T., Klimpe S., Wagner-Heck M., Arnold M., Protsenko E., Heuschmann P.U., Conen D., Weber-Kruger M.; FindAF(randomised) Investigators and Coordinators. Holterelectrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol 2017;16:282-290. https://doi.org/10.1016/s1474-4422(17)30002-9

32. Grond M., Jauss M., Hamann G., Stark E., Veltkamp R., Nabavi D., Horn M., Weimar C., Kohrmann M., Wachter R., Rosin L., Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357-3364. https://doi.org/10.1161/strokeaha.113.001884

33. Kishore A., Vail A., Majid A., Dawson J., Lees K.R., Tyrrell P.J., Smith C.J. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520-526. https://doi.org/10.1161/strokeaha.113.003433

34. Мацкеплишвили С.Т., Саидова М.А., Мироненко М.Ю., Сафарова А.Ф., Павлюкова Е.Н., Бощенко А.А., Ярославская Е.И., Ахунова С.Ю., Скидан В.И., Иртюга О.Б., Козленок А.В., Федорова Д.Н. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271. https://doi.org/10.15829/1560-4071-2025-6271

35. Donal E., Lip G.Y., Galderisi M. et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016; 17:355-383. https://doi.org/10.1093/ehjci/jev354

36. Weigner M.J., Thomas L.R., Patel U. et al Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001 Jun 15;110(9):694-702. https://doi.org/10.1016/s0002-9343(01)00716-1

37. Merino J.L., Tamargo J., Blomström-Lundqvist C., Boriani G., Crijns H.J.G.M., Dobrev D., Goette A., Hohnloser S.H., Naccarelli G.V., Reiffel J.A., Tfelt-Hansen J., Martínez Cossiani M., Camm A.J. Practical Compendium of Antiarrhythmic Drugs: A Clinical Consensus Statement of the European Heart Rhythm Association of the ESC. Europace. 2025 Mar 30:euaf076. Epub ahead of print. PMID: 40159403. https://doi.org/10.1093/europace/euaf076

38. Shandong Yu., Heping Zh., Hongwei Li. Cardiac Computed Tomography Versus Transesophageal Echocardiography for the Detection of Left Atrial Appendage Thrombus: A Systemic Review and Meta‐Analysis. Journal of the American Heart Association. 2021;10:e022505. https://doi.org/10.1161/JAHA.121.022505

39. Hunter R.J., Ginks M., Ang R. et all. Impact of variant pulmonary vein anatomy and image integration on long-term outcome after catheter ablation for atrial fibrillation, Europace. 2010;12(12):1691- 1697. https://doi.org/10.1093/europace/euq322

40. Conti A., Canuti E., Mariannini Y., Viviani G., Poggioni C., Boni V., Pini R., Vanni S., Padeletti L., Gensini G.F. Clinical management of atrial fibrillation: early interventions, observation, and structured follow-up reduce hospitalizations. Am J Emerg Med. 2012 Nov;30(9):1962-9. https://doi.org/10.1016/j.ajem.2012.04.022.

41. Han S., Jia R., Cen Z., Guo R., Zhao S., Bai Y., Xie M., Cui K. Early rhythm control vs. rate control in atrial fibrillation: A systematic review and meta-analysis. Front Cardiovasc Med. 2023 Feb 6;10:978637. https://doi.org/10.3389/fcvm.2023.978637

42. Kirchhof P., Camm J., Goete A. et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020;383:1305- 1316 https://doi.org/10.1056/NEJMoa2019422

43. Трошина Е.А., Свириденко Н.Ю., Ванушко В.Э., Румянцев П.О., Фадеев В.В., Петунина Н.А. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. Проблемы эндокринологии. 2014;60(6):67-77. https://doi.org/10.14341/probl201460667-77

44. Koutsaki S., Koutelekos I., Gerogianni G., Koutsaki M., Koukouzeli A., Fouka G., Polikandrioti M. Atrial Fibrillation in Hypertension: Patients' Characteristics. Mater Sociomed. 2018 Mar;30(1):4-9. PMID: 29670471; PMCID: PMC5857058. https://doi.org/10.5455/msm.2018.30.4-9

45. Pinho-Gomes A.C., Azevedo L., Copland E., Canoy D., Nazarzadeh M., Ramakrishnan R., Berge E., Sundström J., Kotecha D., Woodward M., Teo K., Davis B.R., Chalmers J., Pepine C.J., Rahimi K.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Med. 2021 Jun 1;18(6):e1003599. PMID: 34061831; PMCID: PMC8168843. https://doi.org/10.1371/journal.pmed.1003599

46. Чазова И.Е., Голицын С.П., Жернакова Ю.В., Железнова Е.А., Кропачева Е.С., Миронов Н.Ю., Костюкевич М.В., Лайович Л.Ю., Уцумуева М.Д., Юричева Ю.А., Литвин А.Ю., Елфимова Е.М., Рогоза А.Н., Панченко Е.П. Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий. Системные гипертензии. 2021;18(3):105-128. https://doi.org/10.26442/2075.082X.2021.3.201077

47. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316-20. https://doi.org/10.1001/archinte.158.12.1316

48. Santhanakrishnan R., Wang N., Larson M.G., Magnani J.W., McManus D.D., Lubitz S.A., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484-92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614

49. Kotecha D., Piccini J.P. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015 Dec 7;36(46):3250-7. Epub 2015 Sep 28. PMID: 26419625; PMCID: PMC4670966. https://doi.org/10.1093/eurheartj/ehv513

50. Гаглоева Д.А., Миронов Н.Ю., Лайович Л.Ю., Миронова Н.А., Голицын С.П. Взаимосвязь фибрилляции предсердий и хронической сердечной недостаточности. Современные подходы к лечению. Кардиологический вестник. 2021;16(2):5-14. https://doi.org/10.17116/Cardiobulletin2021160215

51. Уцумуева М.Д., Миронов Н.Ю., Голицын С.П., Долгушева Ю.А., Береговых В.В., Шимановский Н.Л. Фибрилляция предсердий у больных с хронической сердечной недостаточностью: общность звеньев патогенеза, принципы лечения, перспективы использования искусственного интеллекта // Вестник Российской академии медицинских наук. 2024;79(2):143-152. https://doi.org/10.15690/vramn16009

52. Pandey A.K, Okaj I., Kaur H., Belley-Cote E.P, Wang J., Oraii A., et al. Sodium-glucose cotransporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2021;10:e022222. https://doi.org/10.1161/JAHA.121.022222

53. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011 Jul 1;108(1):56-62. Epub 2011 Apr 27. PMID: 21529739; PMCID: PMC3181495. https://doi.org/10.1016/j.amjcard.2011.03.004

54. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, Singer DE, Hylek EM, Go AS, Peterson ED, Piccini JP, Fonarow GC. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12;70(11):1325-1335. PMID: 28882229. https://doi.org/10.1016/j.jacc.2017.07.755

55. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term FollowUp Study (LEGACY). J Am Coll Cardiol. 2015 May 26;65(20):2159- 69. Epub 2015 Mar 16. PMID: 25792361. https://doi.org/10.1016/j.jacc.2015.03.002

56. Melissa E Middeldorp, Rajeev K Pathak, Megan Meredith, Abhinav B Mehta, Adrian D Elliott, Rajiv Mahajan, Darragh Twomey, Celine Gallagher, Jeroen M L Hendriks, Dominik Linz, R Doug McEvoy, Walter P Abhayaratna, Jonathan M Kalman, Dennis H Lau, Prashanthan Sanders, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, EP Europace. 2018 Dec 1;20(12):1929-1935. https://doi.org/10.1093/europace/euy117

57. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014 Dec 2;64(21):2222-31. Epub 2014 Nov 24. PMID: 25456757. https://doi.org/10.1016/j.jacc.2014.09.028

58. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013 Jul;126(7):640.e9-17. Epub 2013 Apr 17. PMID: 23601271. https://doi.org/10.1016/j.amjmed.2012.11.024

59. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013 Nov 20;310(19):2050-60. PMID: 24240932. https://doi.org/10.1001/jama.2013.280521

60. Donnellan E, Wazni OM, Kanj M, Baranowski B, Cremer P, Harb S, McCarthy CP, McEvoy JW, Elshazly MB, Aagaard P, Tarakji KG, Jaber WA, Schauer PR, Saliba WI. Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. Europace. 2019 Oct 1;21(10):1476-1483. PMID: 31304532. https://doi.org/10.1093/europace/euz183

61. Donnellan E, Wazni O, Kanj M, Hussein A, Baranowski B, Lindsay B, Aminian A, Jaber W, Schauer P, Saliba W. Outcomes of Atrial Fibrillation Ablation in Morbidly Obese Patients Following Bariatric Surgery Compared With a Nonobese Cohort. Circ Arrhythm Electrophysiol. 2019 Oct;12(10):e007598. https://doi.org/10.1161/CIRCEP.119.007598. Epub 2019 Oct 15. Erratum in: Circ Arrhythm Electrophysiol. 2020 Feb;13(2):e000047. PMID: 31610693. https://doi.org/10.1161/HAE.0000000000000047

62. Jensen MH, Dalgaard F, Rude Laub R, Gottlieb V, Nielsen OW, Hansen J, Hansen ML, Jennum P, Lamberts M; DAN-APNO investigators. Prevalence of sleep apnea in unselected patients with atrial fibrillation by a home-monitoring device: The DANAPNO study. Int J Cardiol Heart Vasc. 2023 May 18;47:101219. PMID: 37576076; PMCID: PMC10422671. https://doi.org/10.1016/j.ijcha.2023.101219

63. Albuquerque FN, Calvin AD, Sert Kuniyoshi FH, Konecny T, Lopez-Jimenez F, Pressman GS, Kara T, Friedman P, Ammash N, Somers VK, Caples SM. Sleep-disordered breathing and excessive daytime sleepiness in patients with atrial fibrillation. Chest. 2012 Apr;141(4):967-973. Epub 2011 Sep 8. PMID: 21903736; PMCID: PMC3318950. https://doi.org/10.1378/chest.11-0975

64. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF, Ammash NM, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004 Jul 27;110(4):364-7. Epub 2004 Jul 12. PMID: 15249509. https://doi.org/10.1161/01.CIR.0000136587.68725.8E

65. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222-2231. https://doi.org/10.1016/j.jacc.2014.09.028

66. Wang, H., Li, J., Gao, Y. et al. Prevalence and factors associated with atrial fibrillation in older patients with obstructive sleep apnea. BMC Geriatr. 2022 Mar 14;22(1):204. https://doi.org/10.1186/s12877-022-02791-4

67. Patel N, Donahue C, Shenoy A, Patel A, El-Sherif N. Obstructive sleep apnea and arrhythmia: a systemic review.Int J Cardiol. 2017;228:967-970. https://doi.org/10.1016/j.ijcard.2016.11.137

68. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S; Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study.Am J Respir Crit Care Med. 2006;173:910-916. https://doi.org/10.1164/rccm.200509-1442OC

69. Peker Y, Holtstrand-Hjälm H, Celik Y, Glantz H, Thunström E. Postoperative atrial fibrillation in adults with obstructive sleep apnea undergoing coronary artery bypass grafting in the RICCADSA cohort. J Clin Med. 2022;11(9):2459. https://doi.org/10.3390/jcm11092459

70. Congrete S, Bintvihok M, Thongprayoon C, et al. Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis. J Evid Based Med. 2018;11(3):145-151. https://doi.org/10.1111/jebm.12313

71. Monahan K, Brewster J, Wang L, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110(3):369-372. https://doi.org/10.1016/j.amjcard.2012.03.037

72. Starkey SY, Jonasson DR, Alexis S, Su S, Johal R, Sweeney P, Brasher PMA, Fleetham J, Ayas N, Orenstein T, Ahmed IH. Screening for Obstructive Sleep Apnea in an Atrial Fibrillation Population: What's the Best Test? CJC Open. 2020 Dec 3;3(4):442-449. PMID: 34027347; PMCID: PMC8129472. https://doi.org/10.1016/j.cjco.2020.09.026

73. Литвин А.Ю., Чазова И.Е., Елфимова Е.М., Певзнер А.В, Полуэктов М.Г., Данилов Н.М., Михайлова О.О., Аксенова А.В. Клинические рекомендации ЕАК/РОС по диагностике и лечению обструктивного апноэ сна у пациентов с сердечно-сосудистыми заболеваниями (2024). Евразийский кардиологический журнал. 2024;(3):6-27. https://doi.org/10.38109/2225-1685-2024-3-6-27

74. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, et al; ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).Am Heart J. 2015; 169:647–654.e2. https://doi.org/10.1016/j.ahj.2014.12.024

75. Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med. 2018;46:5-11. https://doi.org/10.1016/j.sleep.2018.02.013

76. Traaen GM, Aakerøy L, Hunt TE, et al. Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med. 2021;204(5):573-582. https://doi.org/10.1164/rccm.202011-4133OC

77. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA, Al-Mallah MH. Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project. Circulation. 2015 May 26;131(21):1827- 34. Epub 2015 Apr 22. PMID: 25904645. https://doi.org/10.1161/CIRCULATIONAHA.114.014833

78. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):620-5. Epub 2014 Jun 6. PMID: 24907285; PMCID: PMC4230341. https://doi.org/10.1161/CIRCEP.113.001244

79. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol. 2015 Sep 1;66(9):985- 96. Epub 2015 Jun 22. PMID: 26113406. https://doi.org/10.1016/j.jacc.2015.06.488

80. Voskoboinik A, Prabhu S, Ling LH, Kalman JM, Kistler PM. Alcohol and Atrial Fibrillation: A Sobering Review. J Am Coll Cardiol. 2016 Dec 13;68(23):2567-2576. PMID: 27931615. https://doi.org/10.1016/j.jacc.2016.08.074

81. Lim C, Kim TH, Yu HT, Lee SR, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Kim J, Park HW, Choi EK, Kim JB, Lee YS, Joung B. Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. Europace. 2021 Apr 6;23(4):548-556. PMID: 33227134. https://doi.org/10.1093/europace/euaa340

82. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong M, Kotschet E, Kaye D, Taylor AJ, Kistler PM. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020 Jan 2;382(1):20-28. PMID: 31893513. https://doi.org/10.1056/NEJMoa1817591

83. Al-Khatib SM, Allen LaPointe NM, Chatterjee R et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160:760-773. https://doi.org/10.7326/m13-1467

84. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE. 2013;36:122-133. https://doi.org/10.1111/j.1540-8159.2012.03513.x

85. Jafri SH, Xu J, Warsi I, Cerecedo-Lopez CD. Diltiazem versus metoprolol for the management of atrial fibrillation: A systematic review and meta-analysis. Am J Emerg Med. 2021 Oct;48:323- 327. Epub 2021 Jun 30. PMID: 34274577. https://doi.org/10.1016/j.ajem.2021.06.053

86. Hargrove KL, Robinson EE, Lusk KA, Hughes DW, Neff LA, Fowler AL. Comparison of sustained rate control in atrial fibrillation with rapid ventricular rate: Metoprolol vs. Diltiazem. Am J Emerg Med. 2021 Feb;40:15-19. Epub 2020 Dec 3. PMID: 33338675. https://doi.org/10.1016/j.ajem.2020.11.073

87. Ziff OJ, Lane DA, Samra M et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. https://doi.org/10.1136/bmj.h4451

88. Allen LA, Fonarow GC, Simon DN et al. ORBIT‐AF Investigators. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691-2698. https://doi.org/10.1016/j.jacc.2015.04.045

89. Yu HT, Yang PS, Lee H et al. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure — A Nationwide Cohort Study. Circ J. 2018;82:652–658. https://doi.org/10.1253/circj.CJ-17–0669

90. Zehender M, Hohnloser S, Muller B et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992;19:1054-1059. https://doi.org/10.1016/0735-1097(92)90294-w

91. Tse HF, Lam YM, Lau CP et al. Comparison of digoxin versus lowdose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28:446-450. https://doi.org/10.1046/j.1440-1681.2001.03454.x

92. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373. https://doi.org/10.1056/nejmoa1001337

93. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-310. https://doi.org/10.1016/s0735-1097(98)00561-0

94. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A, et al. Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. Clin Exp Emerg Med 2019;6:64-9. https://doi.org/10.15441/ceem.17.286

95. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20. https://doi.org/10.1056/NEJM200105103441901

96. Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martín A, et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol 2014;172:588-94. https://doi.org/10.1016/j.ijcard.2014.01.099

97. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (FlecSL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238-46. https://doi.org/10.1016/S0140-6736(12)60570-4

98. Pluymaekers N, Dudink E, Luermans J, Meeder JG, Lenderink T, Widdershoven J, et al. Early or delayed cardioversion in recentonset atrial fibrillation. N Engl J Med 2019;380: 1499-508. https://doi.org/10.1056/NEJMoa1900353

99. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. “Asymptomatic” persistent or permanent atrial fibrillation: a misnomer in selected patients. Int J Cardiol 2015;185:112-3. https://doi.org/10.1016/j.ijcard.2015.03.122

100. Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2018;268:143-8. https://doi.org/10.1016/j.ijcard.2018.04.034

101. Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated metaanalysis. J Thromb Thrombolysis 2018;45:550-6. https://doi.org/10.1007/s11239-018-1622-5

102. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-80. https://doi.org/10.1161/01.CIR.0000118472.77237.FA

103. Олесин А.И., Смолин З.Ю., Коновалова О.А. и др. Оценка эффективности чреспищеводной электрокардиостимуляции для купирования впервые выявленного трепетания предсердий 1-го типа у больных ишемической болезнью сердца. Терапевтический архив. 2009;81(9):37–41.

104. Зинченко Ю.В. Влияние частоты предсердных волн на эффективность чреспищеводной электрокардиостимуляции у больных с изолированным трепетанием предсердий. Украинский кардиологический журнал. 2010;2:61-67.

105. Сулимов В.А., Дубровский И.А., Канорский С.Г. и др. Чреспищеводная электрическая стимуляция сердца. Москва: ГЭОТАРМедиа, 2015. С. 216. ISBN: 978-5-9704-3209-9.

106. Jacob I, Haft MD, Bernard D, Kosowsky MD et al. Termination of atrial flutter by rapid electrical pacing of the atrium. J Am Coll Cardiol. 1967;20:239-244. https://doi.org/10.1016/0002-9149(67)90084-7

107. Gerd Fröhlig, Semi Sen, Gerd Rettig et al. Termination of atrial flutter during DDD pacing by rapid overdrive stimulation using the implanted pacemaker lead system. J Am Coll Cardiol. 1986;57:483- 485. https://doi.org/10.1016/0002–9149(86)90781–2

108. Peters RW, Weiss DN, Carliner NH et al. Overdrive pacing for atrial flutter. Am J Cardiol. 1994;74:1021-3. https://doi.org/10.1016/0002-9149(94)90852-4

109. Peters RW, Shorofsky SR, Pelini M et al. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999;137:100. https://doi.org/10.1016/s0002-8703(99)70464-3

110. Kochiadakis GE, Igoumenidis NE, Hamilos ME et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99:1721-1725. https://doi.org/10.1016/j.amjcard.2007.01.059

111. Stiell IG, Sivilotti MLA, Taljaard M et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. 2020 Feb 1;395(10221):339-349. https://doi.org/10.1016/S0140-6736(19)32994-0

112. Stiell IG, Clement CM, Symington C et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med. 2007;14:1158–1164. https://doi.org/10.1197/j.aem.2007.07.016

113. Zhang N, Guo JH, Zhang H et al. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract. 2005;59:1395-1400. https://doi.org/10.1111/j.1368-5031.2005.00705.x

114. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950–953. https://doi.org/10.1016/s0002-9149(00)01128-0

115. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recentonset atrial fibrillation with the «pill-in-the-pocket» approach. N Engl J Med. 2004;351:2384–2391. https://doi.org/10.1056/nejmoa041233

116. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542–7. https://doi.org/10.1016/s0735-1097(00)01116-5

117. Saborido CM, Hockenhull J, Bagust A et al. Systematic review and cost-effectiveness evaluation of «pill-in-the-pocket» strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess. 2010;14:iii–iv,1–75. https://doi.org/10.3310/hta14310

118. Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-thepocket” approach. N Engl J Med 2004;351:2384-91. https://doi.org/10.1056/NEJMoa041233

119. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121–8. https://doi.org/10.1016/S0167-5273(02)00467-9

120. Chevalier P, Durand-Dubief A, Burri H et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC. 2003;41:255–262. https://doi.org/10.1016/s0735-1097(02)02705-5

121. Vardas PE, Kochiadakis GE, Igoumenidis NE et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538- 1545. https://doi.org/10.1378/chest.117.6.1538

122. Bianconi L, Castro A, Dinelli M et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, doubleblind, placebo-controlled study. Eur Heart J. 2000;21:1265-1273. https://doi.org/10.1053/euhj.1999.2039

123. Юричева Ю.А., Соколов С.Ф., Голицын С.П., Миронов Н.Ю., Ривин А.Е., Берман М.В., Шубик Ю.В., Зотова И.В., Затейщиков Д.А., Болотова М.Н., Розенштраух Л.В., Чазов Е.И. Новый антиаритмический препарат III класса ниферидил как эффективное средство восстановления синусового ритма при персистирующей форме мерцательной аритмии. Вестник аритмологии. 2012;70(70):32-43.

124. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А. и соавт. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 2: оценка безопасности. Рациональная фармакотерапия в кардиологии. 2018;14(6):826-830. https://doi.org/10.20996/1819-6446-2018-14-6-826-830

125. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А. и соавт. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):664-669. https://doi.org/10.20996/1819-6446-2018-14-5-664-669

126. Дзаурова Х.М., Миронов Н.Ю., Юричева Ю.А. и соавт. Эффективность и безопасность применения модифицированного протокола введения отечественного антиаритмического препарата III класса для купирования пароксизмальной формы фибрилляции предсердий. Терапевтический архив. 2021;93(9):1052- 1057. https://doi.org/10.26442/00403660.2021.09.201008

127. Миронов Н.Ю., Юричева Ю.А., Влодзяновский В.В. и соавт. Опыт клинического применения отечественного антиаритмического препарата III класса для медикаментозной кардиоверсии фибрилляции и трепетания предсердий: результаты многоцентрового исследования. Часть 1: методология исследования и оценка эффективности. Рациональная фармакотерапия в кардиологии. 2021;17(2):193-199. https://doi.org/10.20996/1819-6446-2021-03-05

128. Миронов Н.Ю., Юричева Ю.А., Влодзяновский В.В., Соколов С.Ф., Дзаурова Х.М., Голицын С.П., Шубик Ю.В., Берман М.В., Медведев М.М., Ривин А.Е., Пархомчук Д.С., Барыбин А.Е., Баландин Д.А., Баталов Р.Е., Терехов Д.В., Евстифеев И.В., Кильдеев И.Р., Пятаева О.В., Зенин С.А. Опыт клинического применения отечественного антиаритмического препарата III класса для медикаментозной кардиоверсии фибрилляции и трепетания предсердий: результаты многоцентрового исследования. Часть 2: оценка безопасности лечения. Рациональная Фармакотерапия в Кардиологии. 2021;17(5):668-673. https://doi.org/10.20996/1819-6446-2021-10-06

129. Гаглоева Д.А., Миронов Н.Ю., Дзаурова Х.М., Зельберг М.А., Юричева Ю.А., Соколов С.Ф., Голицын С.П. Результаты проспективного рандомизированного исследования по сравнению эффективности и безопасности применения рефралона и амиодарона для восстановления синусового ритма у больных пароксизмальной формой фибрилляции и трепетания предсердий. Вестник аритмологии. 2024;31(1):63-70. https://doi.org/10.35336/VA-1289

130. Гаглоева Д.А., Дзаурова Х.М., Зельберг М.А., Миронов Н.Ю., Юричева Ю.А., Соколов С.Ф., Голицын С.П. Эффективность и безопасность раннего назначения противорецидивной антиаритмической терапии у пациентов с фибрилляцией и трепетанием предсердий после медикаментозной кардиоверсии рефралоном. Кардиология. 2023;63(6):21-27. https://doi.org/10.18087/cardio.2023.6.n2276

131. Гаглоева Д.А., Дзаурова Х.М., Зельберг М.А, Миронов Н.Ю., Юричева Ю.А., Соколов С.Ф., Крымукова М.А., Салпагарова А.И., Дулаев Л.О., Певзнер Д.В., Голицын С.П. Предварительные результаты проспективного рандомизированного исследования по сравнению эффективности и безопасности рефралона и амиодарона при кардиоверсии у больных пароксизмальной формой фибрилляции и трепетания предсердий. Кардиоваскулярная терапия и профилактика. 2023;22(4):3527. EDN EKXLTQ https://doi.org/10.15829/1728-8800-2023-3527

132. Зельберг М.А., Миронов Н.Ю., Дзаурова Х.М., Юричева Ю.А., Майков Е.Б., Новиков П.С., Гаглоева Д.А., Крымукова М.А., Соколов С.Ф., Голицын С.П. Медикаментозная кардиоверсия кавутилидом (рефралоном) у пациентов с ранними рецидивами фибрилляции и трепетания предсердий после катетерной аблации легочных вен. Евразийский кардиологический журнал. Май 2024;(2):86-95. https://doi.org/10.38109/2225-1685-2024-2-86-95

133. Boahene KA, Klein GJ, Yee R et al. Termination of acute atrial fibrillation in the Wolff — Parkinson — White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol.1990;16:1408-1414. https://doi.org/10.1016/0735-1097(90)90384-2

134. Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff — Parkinson — White syndrome: electrophysiologic findings and long- term follow-up. J Am Coll Cardiol. 1987;9:1357-1363. https://doi.org/10.1016/s0735-1097(87)80478-3

135. Sellers TD, Bashore TM, Gallagher JJ. Digitalis in the preexcitation syndrome. Analysis during atrial fibrillation. Circulation. 1977;56:260-7. https://doi.org/10.1161/01.cir.56.2.260

136. Sheinman BD, Evans T. Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. Br Med J (Clin Res Ed). 1982; 285:999-1000. https://doi.org/10.1136/bmj.285.6347.999

137. Boriani G, Biffi M, Frabetti L, et al.. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. AmHeartJ. 1996;131:1214-6. https://doi.org/10.1016/s0002-8703(96)90098-8

138. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-183. https://doi.org/10.1056/nejmoa021328

139. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. https://doi. org/10.1056/nejmoa021375

140. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-920. https://doi.org/10.1056/nejm200003303421302

141. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667- 2677. https://doi.org/10.1056/nejmoa0708789

142. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009;30:2969- 2977. https://doi.org/10.1093/eurheartj/ehp235

143. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418-423. https://doi.org/10.1016/s0002-9149(96)00779-5

144. Dogan A, Ergene O, Nazli C et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol. 2004;59:255-61. https://doi.org/10.2143/ac.59.3.2005179

145. Pritchett EL, Page RL, Carlson M et al. Efficacy and safety of sustained release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003;92:941-6. https://doi.org/10.1016/s0002-9149(03)00974-3

146. Курбанов Р.Д., Абдуллаев Т.А. Фармакодинамика и эффективность аллапинина у больных с нарушениями ритма сердца. Клиническая медицина. 1988;10:52–55.

147. Kokina B, Strēlnieks A, Pupkeviča I, Jubele K, Vikmane M, Sakne S, Sokolova E, Urtāne I, Lejnieks A, Kalējs O. Sinus Rhythm Maintenance After Electrical Cardioversion for Atrial Fibrillation in High-Risk Patients — Comparative Efficacy of Antiarrhythmic Medications. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Sciendo, 2021;75:(1):32-39. https://doi.org/10.2478/prolas-2021-0006

148. Недоступ А.В., Благова О.В. Этацизин: место в лечении аритмий. Кардиология и сердечно-сосудистая хирургия. 2009;4:62–68. [Nedostup A.V., Blagova O.V. Etacizin: in the treatment of arrhythmias. Cardiology and cardiovascular surgery. 2009;4:62–68. (In Russ.)]

149. Батушкин В.В., Науменко Е.В. Эффективная фармакологическая поддержка синусового ритма у больных с персистирующей формой фибрилляции предсердий. Украинский кардиологический журнал. 2005;2:65-70.

150. Лозинский Л.Г., Замотаев И.П., Керимова Р.Э. и др. Результаты лечения пароксизмальной мерцательной аритмии этацизином®. Кардиология. 1989;7:37-40.

151. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial.N Engl J Med.1991;324:781–8. https://doi.org/10.1056/nejm199103213241201

152. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385-1394. https://doi.org/10.1016/j.ehj.2004.04.015

153. Рахманова М.М., Соколов С.Ф. Эффективность аллапинина в сравнении с хинидина бисульфатом в предупреждении рецидивов персистирующей фибрилляции предсердий после восстановления синусового ритма. Кардиология. 2014; 54:(9)33- 38. https://doi.org/10.18565/cardio.2014.9.33-38

154. Ревишвили А.Ш., Голицын С.П., Аксентьев С.Б., Амирасланов А.Ю., Артюхина Е.А., Дупляков Д.В., Зубов Е.В., Исаева Е.Н., Логинова А.И., Малкина Т.А., Милосердов Г.И., Ривин А.Е., Теплых С.В., Цыганкова И.А., Шварц Ю.Г., Юричева Ю.А., Канорский С.Г., Соколов С.Ф. Сравнительное исследование лаппаконитина гидробромида пролонгированного и пропафенона у пациентов с пароксизмальной фибрилляцией предсердий. Врач. 2024;35:(1):20-26.

155. Кейко О.И., Регушевская Д.В., Благова О.В., Новикова Н.А., Сыркин А.Л. Возможности применения этацизина в лечении пациентов с фибрилляцией предсердий. Кардиология и сердечно-сосудистая хирургия. 2011;4(6):53-56.

156. Подзолков В.И., Тарзиманова А.И., Моххамади Л.Н. Прогрессирование фибрилляции предсердий у больных артериальной гипертензией при выборе различной тактики лечения аритмии. Кардиология. 2017;57(11):29-33. https://doi.org/10087/cardio.2017.11.10051

157. Valembois L, Audureau E, Takeda A, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9(9):CD005049. https://doi.org/10.1002/14651858.cd005049.pub5

158. Gulizia M, Mangiameli S, Orazi S, et al. PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J. 2008;155(1):100–107, 107.e1, PMID: 18082498. https://doi.org/10.1016/j.ahj.2007.08.033

159. Allen LaPointe NM, Dai D, Thomas L, Piccini JP, Peterson ED, Al-Khatib SM. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. Am J Cardiol. 2015 Feb 1;115(3):316-22. https://doi.org/10.1016/j.amjcard.2014.11.005

160. Сычев О.С., Романова Е.Н., Срибная О.В. Результаты клинического исследования «оценка эффективности и безопасности препарата этацизина у больных с нарушениями ритма без выраженной органической патологии сердца». Аритмология. 2016;3(19):3-10.

161. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–1872. https://doi.org/10.1056/nejmoa041705

162. Bellandi F, Simonetti I, Leoncini M et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88:640–5. https://doi.org/10.1016/s0002-9149(01)01806-9

163. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385-1394. https://doi.org/10.1016/j.ehj.2004.04.015

164. Benditt DG, Williams JH, Jin J et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270-7. https://doi.org/10.1016/s0002-9149(99)00275-1

165. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-920. https://doi.org/10.1056/nejm200003303421302

166. Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201-8. https://doi.org/10.1016/j.jacc.2003.11.032

167. Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329-45. https://doi.org/10.1093/europace/euq450

168. Goldschlager N, Epstein AE, Naccarelli GV et al. Practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-1259. https://doi.org/10.1016/j.hrthm.2007.07.020

169. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16:43-48. https://doi.org/10.1155/2009/282540

170. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic. Survival ventricular arrhythmia Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82. https://doi.org/10.1056/nejm199507133330201

171. Lévy S. Combination therapy for cardiac arrhythmias. The American Journal of Cardiology. 1988 Jan 15;61(2):95A-101A. https://doi.org/10.1016/0002-9149(88)90749-7

172. Narayan G, Akhtar M, Sra J. Combined use of 1C and III agents for highly symptomatic, 29 refractory atrial fibrillation. J Interv Card Electrophysiol 2006;15:175-8. https://doi.org/10.1007/s10840-006-9002-z

173. Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: a new 31 combination therapy for refractory supraventricular tachycardia in children <1 year of age. 32 J Am Coll Cardiol 2002;39:517-20. https://doi.org/10.1016/s0735-1097(01)01773-9

174. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010 May 25;55(21):2299-307. https://doi.org/10.1016/j.jacc.2010.01.043

175. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008 Jan-Feb;15(1):36-43. https://doi.org/10.1097/MJT.0b013e31804beb59

176. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014 May;35(18):1205-14. Epub 2013 Dec 17. https://doi.org/10.1093/eurheartj/eht507

177. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003 Dec;24(23):2090-8. https://doi.org/10.1016/j.ehj.2003.08.014

178. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666. https://doi.org/10.1056/nejm199809033391003

179. Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024 Mar 30;26(4):euae043. https://doi.org/10.1093/europace/euae043. Corrected and republished in: Heart Rhythm. 2024 Sep;21(9):e31-e149. PMID: 38587017; PMCID: PMC11000153. https://doi.org/10.1016/j.hrthm.2024.03.017

180. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316-24. https://doi.org/10.1056/nejmoa2029554

181. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305-315. https://doi.org/10.1056/nejmoa2029980

182. Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace 2021;23:1033-41. https://doi.org/10.1093/europace/euab029

183. Andrade JG, Wazni OM, Kuniss M, Hawkins NM, Deyell MW, Chierchia GB, et al. Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:914-30. https://doi.org/10.1016/j.jacc.2021.06.038

184. Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am Coll Cardiol 2020;75:3105-18. https://doi.org/10.1016/j.jacc.2020.04.065

185. Monahan KH, Bunch TJ, Mark DB, Poole JE, Bahnson TD, Al-Khalidi HR, et al. Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. Europace 2022;24:1430- 40. https://doi.org/10.1093/europace/euac055

186. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. https://doi.org/10.1056/NEJMoa1707855

187. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016 Apr 26;133(17):1637-44. Epub 2016 Mar 30. https://doi.org/10.1161/CIRCULATIONAHA.115.019406

188. PrabhuS, TaylorAJ, CostelloBT et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017 Oct 17;70(16):1949-1961. https://doi.org/10.1016/j.jacc.2017.08.041

189. Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Gellér L, Kalējs O, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace 2021;23:362-9. https://doi.org/10.1093/europace/euaa298

190. Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med 2022;388:105-16. https://doi.org/10.1056/nejmoa2212540

191. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022;43:1219-30. https://doi.org/10.1093/eurheartj/ehab593

192. Bertaglia E, Anselmino M, Zorzi A, Russo V, Toso E, Peruzza F, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol 2017;249:179-83. https://doi.org/10.1016/j.ijcard.2017.07.048

193. Lurie A, Wang J, Hinnegan KJ, McIntyre WF, Belley-Côté EP, Amit G, et al. Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2021;77:2875-86. https://doi.org/10.1016/j.jacc.2021.04.036

194. Lip GY, Frison L, Grind M. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008;264:50- 61. https://doi.org/10.1111/j.1365-2796.2007.01909.x

195. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464-71. https://doi.org/10.1093/eurheartj/eht135

196. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-96. https://doi.org/10.1093/eurheartj/ehu359

197. Patel K, Natale A, Yang R, Trivedi C, Romero J, Briceno D, et al. Is transesophageal echocardiography necessary in patients undergoing ablation of atrial fibrillation on an uninterrupted direct oral anticoagulant regimen? Results from a prospective multicenter registry. Heart Rhythm 2020;17:2093-9. https://doi.org/10.1016/j.hrthm.2020.07.017

198. Wang Y, Zhao Y, Zhou K, Zei PC, Wang Y, Cheng H, et al. Intracardiac echocardiography is a safe and effective alternative to transesophageal echocardiography for left atrial appendage thrombus evaluation at the time of atrial fibrillation ablation: the ICE-TEE study. Pacing Clin Electrophysiol 2023;46:3-10. https://doi.org/10.1111/pace.14601

199. Baran J, Stec S, Pilichowska-Paszkiet E, Zaborska B, SikoraFrąc M, Kryński T, et al. Intracardiac echocardiography for detection of thrombus in the left atrial appendage: comparison with transesophageal echocardiography in patients undergoing ablation for atrial fibrillation: the Action-Ice I study. Circ Arrhythm Electrophysiol 2013;6:1074-81. https://doi.org/10.1161/circep.113.000504

200. Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-center study on postablation thrombo embolic and haemorrhagic events. Europace 2019;21:259–67. https://doi.org/10.1093/europace/euy148

201. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550-6. https://doi.org/10.1161/circulationaha.109.921320

202. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, AlAhmad A, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a metaanalysis. Circ Arrhythm Electrophysiol 2012;5:302-11. https://doi.org/10.1161/circep.111.964916

203. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116:2531-4. https://doi.org/10.1161/circulationaha.107.727784

204. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129: 2638-44. https://doi.org/10.1161/circulationaha.113.006426

205. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–11. https://doi.org/10.1093/eurheartj/ehv177

206. Kuck KH1, Brugada J1, Fürnkranz A1, Metzner A1, Ouyang F1, Chun KR1, Elvan A1, Arentz T1, Bestehorn K1, Pocock SJ1, Albenque JP1, Tondo C1; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. https://doi.org/10.1056/NEJMoa1602014

207. Squara F, Latcu DG, Massaad Y, Mahjoub M, Bun SS, Saoudi N. Contact force and force-time integral in atrial radiofrequency ablation predict transmurality of lesions. Europace 2014;16:660-7. https://doi.org/10.1093/europace/euu068

208. Whitaker J, Fish J, Harrison J, Chubb H, Williams SE, Fastl T, et al. Lesion index-guided ablation facilitates continuous, transmural, and durable lesions in a porcine recovery model. Circ Arrhythm Electrophysiol 2018;11:e005892. https://doi.org/10.1161/circep.117.005892

209. Taghji P, El Haddad M, Phlips T, Wolf M, Knecht S, Vandekerckhove Y, et al. Evaluation of a strategy aiming to enclose the pulmonary veins with contiguous and optimized radiofrequency lesions in paroxysmal atrial fibrillation: a pilot study. JACC Clin Electrophysiol 2018;4:99-108. https://doi.org/10.1016/j.jacep.2017.06.023

210. Das M, Loveday JJ, Wynn GJ, Gomes S, Saeed Y, Bonnett LJ, et al. Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. Europace 2017;19:775– 83. https://doi.org/10.1093/europace/euw105

211. Reddy VY, Shah D, Kautzner J, Schmidt B, Saoudi N, Herrera C, et al. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm 2012;9:1789–95. https://doi.org/10.1016/j.hrthm.2012.07.016

212. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6: 327–33. https://doi.org/10.1161/circep.113.000374

213. Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, et al. EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. Europace 2015;17:1229–35. https://doi.org/10.1093/europace/euv057

214. Andrade JG, Monir G, Pollak SJ, Khairy P, Dubuc M, Roy D, et al. Pulmonary vein isolation using “contact force” ablation: the effect on dormant conduction and long-term freedom from recurrent atrial fibrillation—a prospective study. Heart Rhythm 2014; 11:1919–24. https://doi.org/10.1016/j.hrthm.2014.07.033

215. Duytschaever M, Vijgen J, De Potter T, Scherr D, Van Herendael H, Knecht S, et al. Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicenter VISTAX trial. Europace 2020;22:1645–52. https://doi.org/10.1093/europace/euaa157

216. Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T, et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the CLOSE to CURE study. Heart Rhythm 2020;17:535- 43. https://doi.org/10.1016/j.hrthm.2019.11.004

217. Phlips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y, et al. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the ‘CLOSE’- protocol. Europace 2018;20:f419–27. https://doi.org/10.1093/europace/eux376

218. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation 2019;140:1779–88. https://doi.org/10.1161/circulationaha.119.042622

219. Heeger CH, Popescu SS, Saraei R, Kirstein B, Hatahet S, Samara O, et al. Individualized or fixed approach to pulmonary vein isolation utilizing the fourth-generation cryoballoon in patients with paroxysmal atrial fibrillation: the randomized INDI-FREEZE trial. Europace 2022;24:921–7. https://doi.org/10.1093/europace/euab305

220. Ferrero-de-Loma-Osorio Á, García-Fernández A, Castillo-Castillo J, Izquierdo-de- Francisco M, Ibáñez-Críado A, Moreno-Arribas J, et al. Time-to-effect-based dosing strategy for cryoballoon ablation in patients with paroxysmal atrial fibrillation: results of the plusONE multicenter randomized controlled noninferiority trial. CircArrhythm Electrophysiol 2017;10:e005318. https://doi.org/10.1161/circep.117.005318

221. Verma A1, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 May 7;372(19):1812-22. https://doi.org/10.1056/NEJMoa1408288

222. Buch E, Share M, Tung R, Benharash P, Sharma P, Koneru J, Mandapati R, Ellenbogen KA, Shivkumar K. Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: A multicenter experience. Heart Rhythm. 2016 Mar;13(3):636-41. https://doi.org/10.1016/j.hrthm.2015.10.031

223. Vogler J, Willems S, Sultan A, Schreiber D, Lüker J, Servatius H, et al. Pulmonary vein isolation versus defragmentation: the CHASEAF clinical trial. J Am Coll Cardiol 2015;66: 2743–52. https://doi.org/10.1016/j.jacc.2015.09.088

224. Suenari K, Chen YC, Kao YH, Cheng CC, Lin YK, Chen YJ, et al. Discrepant electrophysiological characteristics and calcium homeostasis of left atrial anterior and posterior myocytes. Basic Res Cardiol 2011;106:65–74. https://doi.org/10.1007/s00395-010-0132-1

225. Markides V, Schilling RJ, Ho SY, Chow AW, Davies DW, Peters NS. Characterization of left atrial activation in the intact human heart. Circulation 2003;107:733–9. https://doi.org/10.1161/01.cir.0000048140.31785.02

226. Hou Y, Zhou Q, Po SS. Neuromodulation for cardiac arrhythmia. Heart Rhythm 2016; 13:584–92. https://doi.org/10.1016/j.hrthm.2015.10.001

227. Armour JA, Murphy DA, Yuan BX, Macdonald S, Hopkins DA. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat Rec 1997;247:289–98. https://doi.org/10.1002/10.1002/(SICI)1097-0185(199702)247:2<289::AIDAR15>3.0.CO;2-L

228. Bisignani A, Pannone L, Miraglia V, Sieira J, Iacopino S, Bala G, et al. Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation. Pacing Clin Electrophysiol 2022;45:605–11. https://doi.org/10.1111/pace.14495

229. Aryana A, Baker JH, Espinosa Ginic MA, Pujara DK, Bowers MR, O’Neill PG, et al. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: a multicenter experience. Heart Rhythm 2018;15:1121–9. https://doi.org/10.1016/j.hrthm.2018.05.014

230. Aryana A, Allen SL, Pujara DK, Bowers MR, O’Neill PG, Yamauchi Y, et al. Concomitant pulmonary vein and posterior wall isolation using cryoballoon with adjunct radiofrequency in persistent atrial fibrillation. JACC Clin Electrophysiol 2021;7:187–96. https://doi.org/10.1016/j.jacep.2020.08.016

231. Ahn J, Shin DG, Han SJ, Lim HE. Does isolation of the left atrial posterior wall using cryoballoon ablation improve clinical outcomes in patients with persistent atrial fibrillation? A prospective randomized controlled trial. Europace 2022;24:1093–101. https://doi.org/10.1093/europace/euac005

232. Bisbal F, Benito E, Teis A, Alarcón F, Sarrias A, Caixal G, et al. Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial. Circ Arrhythm Electrophysiol 2020;13:e008707. https://doi.org/10.1161/circep.120.008707

233. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the DECAAF II randomized clinical trial. JAMA 2022;327:2296–305. https://doi.org/10.1001/jama.2022.8831

234. Wu L, Narasimhan B, Ho KS, Zheng Y, Shah AN, Kantharia BK. Safety and complications of catheter ablation for atrial fibrillation: predictors of complications from an updated analysis the national inpatient database. J Cardiovasc Electrophysiol 2021;32: 1024–34. https://doi.org/10.1111/jce.14979

235. Ngo L, Ali A, Ganesan A, Woodman R, Adams R, Ranasinghe I. Ten-year trends in mortality and complications following catheter ablation of atrial fibrillation. Eur Heart J Qual Care Clin Outcomes 2022;8:398–408. https://doi.org/10.1093/ehjqcco/qcab102

236. Benali K, Khairy P, Hammache N, Petzl A, Da Costa A, Verma A, et al. Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll Cardiol 2023;81:2089–99. https://doi.org/10.1016/j.jacc.2023.03.418

237. Hsu JC, Darden D, Du C, Marine JE, Nichols S, Marcus GM, et al. Initial findings from the national cardiovascular data registry of atrial fibrillation ablation procedures. J Am Coll Cardiol 2023;81:867–78. https://doi.org/10.1016/j.jacc.2022.11.060

238. Tonchev IR, Nam MCY, Gorelik A, Kumar S, Haqqani H, Sanders P, et al. Relationship between procedural volume and complication rates for catheter ablation of atrial fibrillation: a systematic review and metaanalysis. Europace 2021;23:1024–32. https://doi.org/10.1093/europace/euaa415

239. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes. Ann Thorac Surg 2017;104:493–500. https://doi.org/10.1016/j.athoracsur.2017.05.016

240. Budera P, Straka Z, Osmančík P, Vaněk T, Jelínek Š, Hlavička J, et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicenter study. Eur Heart J 2012;33: 2644–52. https://doi.org/10.1093/eurheartj/ehs290

241. Nashef SAM, Fynn S, Abu-Omar Y, Spyt TJ, Mills C, Everett CC, et al. Amaze: a randomized controlled trial of adjunct surgery for atrial fibrillation. Eur J Cardiothorac Surg 2018;54:729–37. https://doi.org/10.1093/ejcts/ezy165

242. Osmancik P, Budera P, Talavera D, Hlavicka J, Herman D, Holy J, et al. Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study. Heart Rhythm 2019;16:1334–40. https://doi.org/10.1016/j.hrthm.2019.05.001

243. Wong JW, Mak KH. Impact of maze and concomitant mitral valve surgery on clinical outcomes. Ann Thorac Surg 2006;82:1938–47. https://doi.org/10.1016/j.athoracsur.2006.05.108

244. Lee R, McCarthy PM, Wang EC, Vaduganathan M, Kruse J, Malaisrie SC Jr, et al. Midterm survival in patients treated for atrial fibrillation: a propensity-matched comparison to patients without a history of atrial fibrillation. J Thorac Cardiovasc Surg 2012; 143:1341–51; discussion 1350–1. https://doi.org/10.1016/j.jtcvs.2012.02.006

245. Musharbash FN, Schill MR, Sinn LA, Schuessler RB, Maniar HS, Moon MR, et al. Performance of the Cox-maze IV procedure is associated with improved long-term survival in patients with atrial fibrillation undergoing cardiac surgery. J Thorac Cardiovasc Surg 2018;155:159–70. https://doi.org/10.1016/j.jtcvs.2017.09.095

246. Iribarne A, DiScipio AW, McCullough JN, Quinn R, Leavitt BJ, Westbrook BM, et al. Surgical atrial fibrillation ablation improves long-term survival: a multicenter analysis. Ann Thorac Surg 2019;107:135–42. https://doi.org/10.1016/j.athoracsur.2018.08.022

247. Kowalewski M, Pasierski M, Kołodziejczak M, Litwinowicz R, Kowalówka A, Wańha W, et al. Atrial fibrillation ablation improves late survival after concomitant cardiac surgery. J Thorac Cardiovasc Surg 2023;166:1656–68.e8. https://doi.org/10.1016/j.jtcvs.2022.04.035

248. Kim HJ, Kim YJ, Kim M, Yoo JS, Kim DH, Park DW, et al. Surgical ablation for atrial fibrillation during aortic and mitral valve surgery: a nationwide population-based cohort study. J Thorac Cardiovasc Surg 2022. https://doi.org/10.1016/j.jtcvs.2022.08.038

249. Suwalski P, Kowalewski M, Jasiński M, Staromłyński J, Zembala M, Widenka K, et al. Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis from the polish national registry of cardiac surgery procedures (KROK). J Thorac Cardiovasc Surg 2019;157:1007–18.e4. https://doi.org/10.1016/j.jtcvs.2018.07.099

250. Gemelli M, Gallo M, Addonizio M, Van den Eynde J, Pradegan N, Danesi TH, et al. Surgical ablation for atrial fibrillation during mitral valve surgery: a systematic review and metaanalysis of randomized controlled trials. Am J Cardiol 2023;209:104–113. https://doi.org/10.1016/j.amjcard.2023.09.088

251. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9:498–505. https://doi.org/10.1093/europace/eum091

252. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation. Heart 2003;89:1035–8. https://doi.org/10.1136/heart.89.9.1035

253. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997;20:343–8. https://doi.org/10.1111/j.1540-8159.1997.tb06179.x

254. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 2013;10:696–701. https://doi.org/10.1016/j.hrthm.2013.01.021

255. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555

256. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42:4731–9. https://doi.org/10.1093/eurheartj/ehab569

257. Sauer WH, Alonso C, Zado E, Cooper JM, Lin D, Dixit S, et al. Atrioventricular nodal reentrant tachycardia in patients referred for atrial fibrillation ablation: response to ablation that incorporates slow-pathway modification. Circulation 2006;114:191–5. https://doi.org/10.1161/circulationaha.106.621896

258. Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1995;25:984–8. https://doi.org/10.1016/0735-1097(94)00512-o

259. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, et al. How many atrial fibrillation ablation candidates have an underlying supraventricular tachycardia previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace 2010;12:1707–12. https://doi.org/10.1093/europace/euq327

260. Delise P, Gianfranchi L, Paparella N, Brignole M, Menozzi C, Themistoclakis S, et al. Clinical usefulness of slow pathway ablation in patients with both paroxysmal atrioventricular nodal reentrant tachycardia and atrial fibrillation. Am J Cardiol 1997;79:1421–3. https://doi.org/10.1016/s0002-9149(97)00157-4

261. Torbey E, Karam B, Sleiman E, Tabet R, Kirk M, Donaldson D, et al. Incidence and risk factors for atrial fibrillation recurrence after ablation of nodal and atrioventricular reentrant tachycardia: a metaanalysis. Cureus 2020;12:e7824. https://doi.org/10.7759/cureus.7824

262. Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ, Klein GJ. When should we recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome? Curr Opin Cardiol 2008;23:32–37. https://doi.org/10.1097/hco.0b013e3282f26d1b

263. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, Gulletta S, Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-ParkinsonWhite syndrome. N Engl J Med 2003;349:1803–1811. https://doi.org/10.1056/nejmoa035345

264. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446–1455. https://doi.org/10.1136/heartjnl-2015-307550

265. Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L, Mantovan R, D’Este D, Zerbo F, Pascotto P. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence. Heart 2004;90:59–63. https://doi.org/10.1136/heart.90.1.59

266. Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM, Manero MR, Grandio PC, Alvarez B, Juanatey JG. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter. Clin Res Cardiol 2014;103:543–552. https://doi.org/10.1007/s00392-014-0682-6

267. Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, Karch MR, Schmitt C. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J 2003;24:956–962. https://doi.org/10.1016/s0195-668x(02)00846-1

268. Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation after typical atrial flutter ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown) 2011;12:110–115. https://doi.org/10.2459/jcm.0b013e3283403301

269. Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter. PLoS One 2014;9:e100509. https://doi.org/10.1371/journal.pone.0100509

270. N M Al-Saady, O A Obel, A J Caam “Left atrial appendage: structure, function, and role in thromboembolism” Heart 1999;82:547-554. https://doi.org/10.1136/hrt.82.5.547

271. Leung DY, Davidson PM, Cranney GB, Walsh WF “Tromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram” Am J Cardiol 1997 Mar 1;79(5):626-9. https://doi. org/10.1016/s0002-9149(96)00828-4

272. Martin SS, Aday AW, Almarzooq ZI et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-e913. https://doi.org/10.1161/CIR.0000000000001209. Epub 2024 Jan 24. Erratum in: Circulation. 2024 May 7;149(19):e1164. PMID: 38264914; PMCID: PMC12146881. https://doi.org/10.1161/CIR.0000000000001247

273. Neyer J., et al. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:69–171. https://doi.org/10.1161/circulationaha.106.179918

274. Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. Руководство по артериальной гипертонии. Ред. Чазов Е.И., Чазова И.Е. М.: Медиа Медика, 2005. 734 с. ISBN:5-9900251-3-0

275. Суслина З.А., Варакин Ю.Я. Профилактика нарушений мозгового кровообращения. Очерки ангионеврологии. Ред. Суслина З.А. М.: Атмосфера, 2005. 368 с. ISBN: 5-902123-19-4

276. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219-27. https://doi.org/10.18632/aging.104133

277. Yamaguchi H, Nishimura YK, Nakaoka Y, Komatsu J, Sugane H, Hosoda H, Imai RI, Nishida K, Seki SI, Kubokawa SI, Kawai K, Hamashige N, Doi Y. Intracardiac Thrombosis and Systemic Embolism in a Patient with Cardiac Amyloidosis in Sinus Rhythm. Int Heart J. 2023 May 31;64(3):491-495. https://doi.org/10.1536/ihj.22-448

278. Francesco Cappelli , Giacomo Tini , Domitilla Russo et al “ Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation” Observational Study Amyloid. 2021 Mar;28(1):12- 18. Epub 2020 Sep 28. PMID: 32981389. https://doi.org/10.1080/13506129.2020.1798922

279. Silvia Vilches , Marianna Fontana , Esther Gonzalez-Lopez et al “Systemic embolism in amyloid transthyretin cardiomyopathy” Eur J Heart Fail. 2022 Aug;24(8):1387-1396. Epub 2022 Jul 11. PMID: 35650018 PMCID: PMC9542906. https://doi.org/10.1002/ejhf.2566

280. Hart R.G., Pearce L.A., Aguilar M.I. “Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation” Ann Intern Med 2007;146:857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007

281. Azzam H, Elwakeel H, Awad I, El-Farahaty R, El-Gilany AH, ElSharawy S. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance. Blood Coagul Fibrinolysis. 2016 Mar;27(2):121-6. PMID: 24978953. https://doi.org/10.1097/MBC.0000000000000168

282. Zhao L, Zhai Z, Li P. One Rare Warfarin Resistance Case and Possible Mechanism Exploration. Pharmgenomics Pers Med. 2023;16:609-615. https://doi.org/10.2147/PGPM.S404474

283. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7(8):e44064. Epub 2012 Aug 29. PMID: 22952875; PMCID: PMC3430615. https://doi.org/10.1371/journal.pone.0044064

284. Курбанов Р.Д., Закиров Н.У., Ирисов Д.Б., Кеворков А.Г., Хусанов Ш.С. Влияние полиморфизма гена CYP2C9 на эффективность варфарина у больных узбекской национальности с длительно существующей фибрилляцией предсердий. Медицинские новости. 2012;9:35-38.

285. Connolly S, Eikelboom J, Joyner C et al. Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;364(9):806-817. https://doi.org/10.1056/nejmoa1007432

286. Robert P Giugliano, Christian T Ruff, Eugene Braunwald et al ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med. 2013 Nov 28;369(22):2093-104. https://doi.org/10.1056/NEJMoa1310907

287. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875-6. https://doi.org/10.1056/nejmc1007378

288. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. Epub 2011 Aug 10. PMID: 21830957. https://doi.org/10.1056/NEJMoa1009638

289. Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92. https://doi.org/10.1056/nejmoa1107039

290. Blackshear, J. L. & Odell, J. A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 1996;61:755–759. https://doi.org/10.1016/0003-4975(95)00887-x

291. Chatterjee, S., Alexander, J. C., Pearson, P. J. & Feldman, T. Left atrial appendage occlusion: lessons learned from surgical and transcatheter experiences. Ann. Thorac. Surg. 2011;92:2283–2292. https://doi.org/10.1016/j.athoracsur.2011.08.044

292. Aryana A, Singh SK, Singh SM, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm. 2015;12(7):1431–1437. https://doi.org/10.1016/j.hrthm.2015.03.028

293. Salzberg SP, Plass A, Emmert MY, Desbiolles L, Alkadhi H, Grünenfelder J, Genoni M. Left atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg. 2010 May;139(5):1269- 74. PMID: 19880144. https://doi.org/10.1016/j.jtcvs.2009.06.033

294. Blackshear JL, Johnson WD, Odell JA, Baker VS, Howard M, Pearce L, Stone C, Packer DL, Schaff HV. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol. 2003 Oct 1;42(7):1249-52. PMID: 14522490. https://doi.org/10.1016/s0735-1097(03)00953-7

295. Whitlock RP, Belley-Cote EP, Paparella D, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. N Engl J Med. 2021 Jun 3;384(22):2081-2091. https://doi.org/10.1056/NEJMoa2101897

296. van Laar C, Verberkmoes NJ, van Es HW, et al. Thoracoscopic Left Atrial Appendage Clipping: A Multicenter Cohort Analysis. JACC Clin Electrophysiol. 2018 Jul;4(7):893-901. https://doi.org/10.1016/j.jacep.2018.03.009

297. Zhang S, Cui Y, Li J, et al. Concomitant transcatheter occlusion versus thoracoscopic surgical clipping for left atrial appendage in patients undergoing ablation for atrial fibrillation: A metaanalysis. Front Cardiovasc Med. 2022 Sep 6;9:970847. https://doi.org/10.3389/fcvm.2022.970847

298. Cartledge R, Suwalski G, Witkowska A, et al. Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):548-555. https://doi.org/10.1093/icvts/ivab334

299. Garg J, Kabra R, Gopinathannair R, et al. State of the Art in Left Atrial Appendage Occlusion. JACC Clin Electrophysiol. 2024 Dec 31:S2405-500X(24)00932-0. https://doi.org/10.1016/j.jacep.2024.10.024

300. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. https://doi.org/10.1016/j.jacc.2017.10.021

301. Saw J, Holmes DR, Cavalcante JL, et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. 2023 May;20(5):e1-e16. PMID: 36990925. https://doi.org/10.1016/j.hrthm.2023.01.007

302. Tzikas A, Holmes DR Jr, Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2016;19(1):4–15. https://doi.org/10.1093/europace/euw141

303. Rezkalla J, Alarouri H, Padang R, et al. The Imaging Spectrum of Device-Related Thrombus After Percutaneous Left Atrial Appendage Occlusion. JACC Case Rep. 2024 Nov 6;29(21):102661. https://doi.org/10.1016/j.jaccas.2024.102661

304. Chatterjee S, Herrmann HC, Wilensky RL, et al. Safety and procedural success of left atrial appendage exclusion with the Lariat device: a systematic review of published reports and analytic review of the FDA MAUDE Database. JAMA Intern Med. 2015;175(7):1104–1109. https://doi.org/10.1001/jamainternmed.2015.1513

305. Urs Fischer, Masatoshi Koga, Daniel Strbian et al ELAN Investigators Early versus Later Anticoagulation for Stroke with Atrial Fibrillation Randomized Controlled Trial N Engl J Med. 2023 Jun 29;388(26):2411-2421. https://doi.org/10.1056/NEJMoa2303048

306. Кулеш АА, Нуриева ЮА, Сыромятникова ЛИ. Причины ишемического инсульта у пациентов моложе 45 лет: анализ данных регионального сосудистого центра. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):24–30. https://doi.org/10.14412/2074-2711-2021-1-24-30

307. Fischer, U Koga, M Strbian, D et al. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 2023; 388:2411-2421 + Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of Direct Oral Anticoagulants for Hemorrhagic Transformation After Endovascular Treatment in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2022 Jul;31(7):106507. https://doi.org/10.1016/j.jstrokecerebrova sdis.2022.106507

308. ACTIVE Investigators; Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78. https://doi.org/10.1056/NEJMoa0901301

309. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998 Oct 20;98(16):1597-603. https://doi.org/10.1161/01.cir.98.16.1597

310. Byrne RA, Rossello X, Coughlan JJ,. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. https://doi.org/10.1093/eurheartj/ehad191

311. Бражник В.А., Минушкина Л.О., Эрлих А.Д., Космачева Е.Д., Чичкова М.А., Хасанов Н.Р., Затейщиков Д.А. Использование шкалы ОРАКУЛ для оценки геморрагического риска у пациентов с острым коронарным синдромом и фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):11-15. https://doi.org/10.20996/1819-6446-2021-01-01

312. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509-1524. https://doi.org/10.1056/NEJMoa1817083

313. Аверков О.В., Арутюнян Г.К., Дупляков Д.В., и соавт. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(3):6306. https://doi.org/10.15829/1560-4071-2025-6306

314. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019 Jan 29;139(5):604-616. https://doi.org/10.1161/CIRCULATIONAHA.118.036768

315. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019 Sep 19;381(12):1103-1113

316. Сho MS, Kang DY, Ahn JM, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024 Dec 5;391(22):2075-2086. https://doi.org/10.1056/nejmoa2407362

317. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. https://doi.org/10.1093/eurheartj/ehad191. Erratum in: Eur Heart J. 2024 Apr 1;45(13):1145. https://doi.org/10.1093/eurheartj/ehad870

318. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-1676. https://doi.org/10.1093/europace/euab065

319. Spyropoulos AC, Brohi K, Caprini J, et al Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019 Nov;17(11):1966- 1972. https://doi.org/10.1111/jth.14598

320. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924. https://doi.org/10.1093/eurheartj/ehac270

321. Douketis JD, Spyropoulos AC, Murad MH, et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022 Nov;162(5):1127-1139. https://doi.org/10.1016/j.chest.2022.08.004

322. Шахматова О.О. Специфические антидоты к новым пероральным антикоагулянтам. Атеротромбоз. 2016;1:81-94. http://dx.doi.org/10.21518/2307-1109-2016-1-81-94

323. Kakkar AK, Mueller I, Bassand JP et al «International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)» AHJ 2012; 163(1):13-19. https://doi.org/10.1016/j.ahj.2011.09.011

324. Ruff C.T., Giugliano R.P., Braunwald E. et al Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014 Aug 12;64(6):576-84. https://doi.org/10.1016/j.jacc.2014.05.028

325. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014 Feb 15;113(4):662-8. https://doi.org/10.1016/j.amjcard.2013.10.044

326. Natalie Tapaskar, Alice Pang, Debra A Werner, Neil Sengupta «Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis» Digestive Diseases and Sciences (2021) Feb;66(2):554-566 https://doi.org/10.1007/s10620-020-06248-9

327. Sigrun Halvorsen, Robert F. Storey, Bianca Rocca, et a. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis, European Heart Journal. 2017 May 14;38(19):1455-1462. https://doi.org/10.1093/eurheartj/ehw454

328. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013;62: 1187–1192. https://doi.org/10.1016/j.jacc.2013.04.089

329. Berger M1, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998 Dec 15;82(12):1545-7, A8.

330. Nuotio I, Hartikainen JE, Grönberg T et al Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014 Aug 13;312(6):647-9. https://doi.org/10.1001/jama.2014.3824

331. Ezekowitz MD; Pollack C.V. Jr; Halperin J.L.; et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018; 39: 2959-2971. https://doi.org/10.1093/eurheartj/ehy148

332. Di Biase L,Burkhardt JD,Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:2638–2644. https://doi.org/10.1161/circulationaha.113.006426

333. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805– 1811. https://doi.org/10.1093/eurheartj/ehv177

334. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627–1636. https://doi.org/10.1056/nejmoa1701005

335. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, Volume 39, Issue 32, Pages 2942–2955, https://doi.org/10.1093/eurheartj/ehy176

336. Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal. 21 September 2019;40(36):3013–3021. https://doi.org/10.1093/eurheartj/ehz190

337. Di Biase L,Burkhardt JD,Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:2638-2644. https://doi.org/10.1161/circulationaha.113.006426

338. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. https://doi.org/10.1093/eurheartj/ehy394

339. Andreas Goette, Jose L Merino, Michael D Ezekowitz et all. ENSURE-AF investigators «Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSUREAF): a randomised, open-label, phase 3b trial». Lancet. 2016 Oct 22;388(10055):1995-2003. https://doi.org/10.1016/S0140- 6736(16)31474-X

340. Hansen M. L., Jepsen R. M. H. G., Olesen J. B. et al. Thromboembolic risk in 16,274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17:18-23. https://doi.org/10.1093/europace/euu189

341. Jaber WA, Prior DL, Thamilarasan M, et al Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. Am Heart J. 2000 Jul;140(1):150-6. https://doi.org/10.1067/mhj.2000.106648

342. Heidbuchel H, Verhamme P, Alings M, et al Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015 Oct;17(10):1467-507. https://doi.org/10.1093/europace/euv309

343. Renda G, Zimarino M, Ricci F1, et al Efficacy and Safety of NonVitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. Am J Med. 2016 Oct;129(10):1117- 1123.e2. https://doi.org/10.1016/j.amjmed.2016.05.007

344. Whitlock RP, Belley-Cote EP, Paparella D, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. N Engl J Med. 2021 Jun 3;384(22):2081-2091. https://doi.org/10.1056/NEJMoa2101897

345. Zhang S, Cui Y, Li J, et al. Concomitant transcatheter occlusion versus thoracoscopic surgical clipping for left atrial appendage in patients undergoing ablation for atrial fibrillation: A metaanalysis. Front Cardiovasc Med. 2022 Sep 6;9:970847. https://doi.org/10.3389/fcvm.2022.970847

346. Cartledge R, Suwalski G, Witkowska A, et al. Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):548-555. https://doi.org/10.1093/icvts/ivab334

347. Cannon C, Bhatt D, Oldgren J et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine. 2017;377(16):1513-1524. https://doi.org/10.1056/nejmoa1708454

348. Lopes RD, Heizer G, Aronson R et al AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509-1524. https://doi.org/10.1056/NEJMoa1817083

349. Gibson CM, Mehran R, Bode C et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose- adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169:472–478.e5. https://doi.org/10.1016/j.ahj.2014.12.006

350. Pascal Vranckx, Marco Valgimigli, Lars Eckardt et all. «Edoxabanbased versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial» Lancet. 2019 Oct 12;394(10206):1335-1343. https://doi.org/10.1016/S0140-6736(19)31872-0

351. Lopes RD, Hong H, Harskamp RE, et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Metaanalysis of Randomized Controlled Trials. JAMA Cardiol. 2019 Aug 1;4(8):747-755. https://doi.org/10.1001/jamacardio.2019.1880

352. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 2016;13:131. https://doi.org/10.1038/nrcardio.2015.191

353. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation like fire and fury. JACC Heart Fail 2019;7:447-456. https://doi.org/10.1016/j.jchf.2019.03.005

354. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, Marin F, Masip J, Mueller C, Okutucu S, Poess J, Potpara TS, Price S, Lip GYH. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care 2020;9:348-357. https://doi.org/10.1177/2048872619894255

355. Slawik J, Adrian L, Hohl M, Lothschutz S, Laufs U, Bohm M. Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. Eur J Heart Fail 2019;21:482-491. https://doi.org/10.1002/ejhf.1392

356. Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 2016;68:2217-2228. https://doi.org/10.1016/j.jacc.2016.08.048

357. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, van Veldhuisen DJ, Van Gelder IC. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14:1030-1040. https://doi.org/10.1093/eurjhf/hfs097

358. Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer JH, et al. Incidence and predictors of atrial fibrillation progression. J Am Heart Assoc 2019;8:e012554. https://doi.org/10.1161/JAHA.119.012554

359. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250–7. https://doi.org/10.1093/eurheartj/ehv513

360. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316–20. https://doi.org/10.1001/archinte.158.12.1316

361. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events — European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open 2019;9:e022478. https://doi.org/10.1136/bmjopen-2018-022478

362. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484–92. https://doi.org/10.1161/circulationaha.115.018614

363. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660–6. https://doi.org/10.1016/j.ijcard.2015.10.220

364. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286

365. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038

366. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117–28. https://doi.org/10.1056/NEJMoa2030183

367. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962. https://doi.org/10.1016/s0140-6736(13)62343-0

368. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and metaanalysis of randomized trials. Eur J Heart Fail 2015;17:1192-1200. https://doi.org/10.1002/ejhf.343

369. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410

370. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ, RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-942. https://doi.org/10.1093/europace/eul106

371. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, Bhatt DL, Allen LA, Peterson PN, Ho PM, Lewis WR, Hernandez AF, Fonarow GC, Piccini JP. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines - Heart Failure Program). Am J Cardiol 2020;125:894-900. https://doi.org/10.1016/j.amjcard.2019.12.025

372. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:471-479. https://doi.org/10.1002/ejhf.1389

373. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrilla tion. Lancet 2016;388:818-828. https://doi.org/10.1016/s0140-6736(16)31258-2

374. Jandali MB. Safety of intravenous diltiazem in reduced ejection fraction heart failure with rapid atrial fibrillation. Clin Drug Investig. 2018;38:503–508. Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency depart ment. Am J Emerg Med. 2022;58:39–42. https://doi.org/10.1007/s40261-018-0631-7

375. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000;101:1138-1144. https://doi.org/10.1161/01.cir.101.10.1138

376. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R. Ablate and pace strategy for atrial fibrillation: longterm outcome of AIRCRAFT trial. Europace 2007;9:498-505. https://doi.org/10.1093/europace/eum091

377. Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. Eur J Heart Fail 2018;20:1472-1481. https://doi.org/10.1002/ejhf.1117

378. Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose cotransporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2021;10:e022222. https://doi.org/10.1161/JAHA.121.022222

379. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart FailureAssessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997–2004. https://doi.org/10.1016/j.jacc.2006.01.060

380. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235–43. https://doi.org/10.1016/S0140-6736(14)61373-8

381. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492

382. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/ NEJMoa1409077

383. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368

384. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781- 788. https://doi.org/10.1056/nejm199103213241201

385. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574-2579. https://doi.org/10.1161/01.cir.98.23.2574

386. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Eur Heart J 1992;13:1251-1258. PMID: 1396837

387. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, Cleland JG. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-930. https://doi.org/10.1136/hrt.2008.158931

388. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66 73. https://doi.org/10.1053/euhj.1999.1734

389. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. https://doi.org/10.1056/nejmoa021375

390. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial Fibrillation and Congestive Heart Failure Investigators Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677. https://doi.org/10.1056/nejmoa0708789

391. Chen S, Purerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J. 2020;41:2863–2873. https://doi.org/10.1093/eurheartj/ehz443

392. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, Grammatico A, Leyva F, Boriani G. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. Eur J Heart Fail 2018;20:1472-1481. https://doi.org/10.1002/ejhf.1117

393. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31–8. https://doi.org/10.1161/CIRCEP.113.000806

394. Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389: 1380–9. https://doi.org/10.1056/NEJMoa2306037

395. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 2021;143:1377–90. https://doi.org/10.1161/CIRCULATIONAHA.120.050991

396. Ousdigian KT, Borek PP, Koehler JL, Heywood JT, Ziegler PD, Wilkoff BL. The epidemic of inadequate biventricular pacing in patients with persistent or permanent atrial fibrillation and its association with mortality. Circ Arrhythm Electrophysiol 2014;7:370-376. https://doi.org/10.1161/circep.113.001212

397. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012;5:566-570. https://doi.org/10.1161/circheartfailure.112.968867

398. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012;59:719-726. https://doi. org/10.1016/j.jacc.2011.10.891

399. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani G, Lamp B, Proclemer A, Curnis A, Klersy C, Leyva F. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013;1:500-507. https://doi.org/10.1016/j.jchf.2013.06.003

400. Yin J, Hu H, Wang Y, Xue M, Li X, Cheng W, Li X, Yan S. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis. Clin Cardiol 2014;37:707-715. https://doi.org/10.1002/clc.22312

401. Tolosana JM, Trucco E, Khatib M, Doltra A, Borras R, Castel M, Berruezo A, Arbelo E, Sitges M, Matas M, Guasch E, Brugada J, Mont L. Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. Eur J Heart Fail 2013;15:1412-1418. https://doi.org/10.1093/eurjhf/hft114

402. Уцумуева М.Д., Миронова Н.А., Каштанова С.Ю., Стукалова О.В. Возможности магнитно-резонансной томографии сердца при отборе кандидатов на сердечную ресинхронизирующую терапию. Медицинская визуализация. 2018;(4):20-31. https://doi.org/10.24835/1607-0763-2018-4-20-31

403. Уцумуева М.Д., Миронова Н.А., Стукалова О.В., Гупало Е.М., Каштанова С.Ю., Малкина Т.А., Киктев В.Г., Голицын С.П. Топография структурного поражения миокарда левого желудочка и последовательность его электрической активации при различной эффективности сердечной ресинхронизирующей терапии у больных с хронической сердечной недостаточностью. Вестник аритмологии. 2019;26(3):5-14. https://doi.org/10.35336/VA-2019-3-5-14

404. Стукалова О.В., Миронова Н.А., Уцумуева М.Д., Каштанова С.Ю., Буторова Е.А., Шитов В.Н., Тарасовский Г.С., Голицын С.П., Терновой С.К. Эффективность сердечной ресинхронизирующей терапии у пациентов с хронической сердечной недостаточностью различной этиологии в зависимости от структурного поражения миокарда по данным магнитно-резонансной томографии сердца с контрастированием. Российский кардиологический журнал. 2019;(12):22-32. https://doi.org/10.15829/1560-4071-2019-12-22-32

405. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012;5:68-76. https://doi.org/10.1161/circep.111.967810

406. Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 2006;48:1642 1648. https://doi.org/10.1016/j. jacc.2006.05.072

407. Brignole M, Botto GL, Mont L, Oddone D, Iacopino S, De Marchi G, Campoli M, Sebastiani V, Vincenti A, Garcia Medina D, Osca Asensi J, Mocini A, Grovale N, De Santo T, Menozzi C. Predictors of clinical efficacy of ‘Ablate and Pace’ therapy in patients with permanent atrial fibrillation. Heart 2012;98:297-302. https://doi.org/10.1136/heartjnl-2011-301069

408. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012;14:1490-1497. https://doi.org/10.1093/europace/eus193

409. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. Europace 2017;19:iv10-iv16. https://doi.org/10.1093/europace/eux263

410. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His Purkinje activation. Circulation 2000;101:869-877. https://doi.org/10.1161/01.cir.101.8.869

411. Sharma PS, Vijayaraman P, Ellenbogen KA. Permanent His bundle pacing: shaping the future of physiological ventricular pacing. Nat Rev Cardiol 2020;17:22-36. https://doi.org/10.1038/s41569-019-0224-z

412. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. A Novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block. Can J Cardiol 2017;33:1736.e1 1736.e73. https://doi.org/10.1016/j.cjca.2017.09.013

413. Sharma PS, Dandamudi G, Herweg B, Wilson D, Singh R, Naperkowski A, Koneru JN, Ellenbogen KA, Vijayaraman P. Permanent Hisbundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a multicenter experience. Heart Rhythm 2018;15:413 420. https://doi.org/10.1016/j.hrthm.2017.10.014

414. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study. Circ Arrhythm Electrophysiol 2019;12:e006934. https://doi.org/10.1161/circep.118.006934

415. Coluccia G, Vitale E, Corallo S, Aste M, Odaglia F, Donateo P, Oddone D, Brignole M. Additional benefits of nonconventional modalities of cardiac resynchronization therapy using His bundle pacing. J Cardiovasc Electrophysiol 2020;31:647-657. https://doi.org/10.1111/jce.14359

416. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:2420-2429. https://doi.org/10.1093/eurheartj/ehr162

417. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol 2009;53:355-360. https://doi.org/10.1016/j.jacc.2008.09.043

418. Hayes DL, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Seth M, Jones PW, Saxon LA. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011;8:1469-1475. https://doi.org/10.1016/j.hrthm.2011.04.015

419. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM, Saliba WI, Varma N, Wilkoff BL, Cantillon DJ. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm 2016;13:2272-2278. https://doi.org/10.1016/j.hrthm.2016.09.027

420. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA, PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160-1165. https://doi.org/10.1111/j.1540-8167.2005.50062.x

421. Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, Fang F, Lam KH, Chan HC, Fung JW. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009;361:2123-2134. https://doi.org/10.1056/nejmoa0907555

422. Morina-Vazquez P, Moraleda-Salas MT, Arce-Leon A, et al. Effectiveness and safety of AV node ablation after His bundle pacing in patients with uncontrolled atrial arrhythmias. Pacing Clin Electrophysiol. 2021;44:1004-1009. https://doi.org/10.1111/pace.14252

423. Pillai A, Kolominsky J, Koneru JN, et al. Atrioventricular junction ablation in patients with conduction system pacing leads: a comparison of His-bundle vs left bundle branch area pacing leads. Heart Rhythm. 2022;19:1116-1123. https://doi.org/10.1016/j.hrthm.2022.03.1222

424. Vijayaraman P, Mathew AJ, Naperkowski A, et al. Conduction system pacing versus conventional pacing in patients undergoing atrioventricular node ablation: nonrandomized, on-treatment comparison. Heart Rhythm O2. 2022;3:368-376. https://doi.org/10.1016/j.hroo.2022.04.005

425. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. Europace. 2017;19:iv10–iv16. https://doi.org/10.1093/europace/eux263

426. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, et al. Atrial fibrillation and atrial flutter in pregnant women—a population-based study. J Am Heart Assoc 2016;5:e003182. https://doi.org/10.1161/JAHA.115.003182

427. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of arrhythmia in pregnancy. Circulation 2017;135:619-21. https://doi.org/10.1161/CIRCULATIONAHA.116.0

428. Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. Arrhythmias in pregnancy. JACC Clin Electrophysiol 2022;8:120-35. https://doi.org/10.1016/j.jacep.2021.10.004

429. Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR, et al. Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015;1:284-92. https://doi.org/10.1016/j.jacep.2015.04.013

430. Chokesuwattanaskul R, Thongprayoon C, Bathini T, O’Corragain OA, Sharma K, Prechawat S, et al. Incidence of atrial fibrillation in pregnancy and clinical significance: a meta-analysis. Adv Med Sci 2019;64:415-22. https://doi.org/10.1016/j.advms.2019.07.003

431. Tamirisa KP, Dye C, Bond RM, Hollier LM, Marinescu K, Vaseghi M, et al. Arrhythmias and heart failure in pregnancy: a dialogue on multidisciplinary collaboration. J Cardiovasc Dev Dis 2022;9:199. https://doi.org/10.3390/jcdd9070199

432. Al Bahhawi T, Aqeeli A, Harrison SL, Lane DA, Skjøth F, Buchan I, et al. Pregnancy-related complications and incidence of atrial fibrillation: a systematic review. J Clin Med 2023;12:1316. https://doi.org/10.3390/jcm12041316

433. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, BlomstromLundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/eurheartj/ehy340

434. Xu, Z. Fan, J. Luo, X. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: A systematic review and meta-analysis Can J Cardiol. 2016; 32:1248.e1241-1248.e1249. https://doi.org/10.1016/j.cjca.2015.11.005

435. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy-systematic review. J Perinat Med 2022;50:457–61. https://doi.org/10.1515/jpm-2021-045

436. Ueberham L, Hindricks G. Anticoagulation in special patient populations with atrial fibrillation. Herz 2021;46:323–8. https://doi. org/10.1007/s00059-021-05042-1

437. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J 2017;19:465–511. https://doi.org/10.1093/europace/euw301

438. Moore JS, Teefey P, Rao K, Berlowitz MS, Chae SH, Yankowitz J. Maternal arrhythmia: a case report and review of the literature. Obstet Gynecol Surv 2012;67:298–312. https://doi.org/10.1097/OGX.0b013e318253a76e

439. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–9. https://doi.org/10.1016/j.ejogrb.200

440. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. β-Blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med 2018;169:665–73. https://doi.org/10.7326/M18-0338

441. Ersboll AS, Hedegaard M, Sondergaard L, Ersboll M, Johansen M. Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG 2014;121:618–626.

442. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990;301:587–9. https://doi.org/10.1136/bmj.301.6752.587

443. Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal supraventricular tachycardias during pregnancy: a review of the literature. J Obstet Gynaecol Can 2011;33:17–23. https://doi.org/10.1016/s1701-2163(16)34767-3

444. Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007;18:545–7. https://doi.org/10.1111/j.1540-8167.2006.00

445. Ramlakhan KP, Kauling RM, Schenkelaars N, Segers D, Yap SC, Post MC, et al. Supraventricular arrhythmia in pregnancy. Heart 2022;108:1674–81. https://doi.org/10.1136/heartjnl-2021-320451

446. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:457–476. https://doi.org/10.1016/j.jacc.2018.10.075

447. Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: A systematic review and meta-analysis. J Am Heart Assoc 2017;6:e007164. https://doi.org/10.1161/jaha.117.007164

448. Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011;124:1747–1754. https://doi.org/10.1161/circulationaha.111.026120

449. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD. Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 2015;26:698–702. https://doi.org/10.1111/jce.12675

450. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001;24:116–130. https://doi.org/10.1007/bf03343825

451. Jouannic JM, Delahaye S, Fermont L, et al. Fetal supraventricular tachycardia: a role for amiodarone as second-line therapy? Prenat Diagn 2003;23:152–156. https://doi.org/10.1002/pd.542

452. Strasburger JF, Cuneo BF, Michon MM, et al. Amiodarone therapy for drugrefractory fetal tachycardia. Circulation 2004;109:375–379. https://doi.org/10.1161/01.cir.0000109494.05317.58